Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04973605 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
A Phase 1 study of Relapsed/Refractory Multiple Myeloma, sponsored by BeOne Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 246
- Enrollment target
- 20
- Study locations
NCT04973605 is a Phase 1 study of Relapsed/Refractory Multiple Myeloma that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 246 participants, above the 153-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (61% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04973605, a Phase 1 study of Relapsed/Refractory Multiple Myeloma, is actively recruiting participants, sponsored by BeOne Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 246 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.
Conditions Studied
Interventions
- DRUG Sonrotoclax
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Carfilzomib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- City of Hope Irvine Lennar - Irvine
- University of California At San Francisco - San Francisco
Illinois
- University of Chicago Medical Center - Chicago
- Southern Illinois University School of Medicine - Springfield
New York
- Weill Cornell Medical College Newyork Presbyterian Hospital - New York
- Memorial Sloan Kettering Cancer Center Mskcc - New York
Wisconsin
- University of Wisconsin Carbone Cancer Center - Madison
- Medical College of Wisconsin - Milwaukee
Alabama
- University of Alabama At Birmingham Hospital - Birmingham
Florida
- University of Miami - Miami
Georgia
- Emory University Winship Cancer Center - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2021-09-16 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04973605
The ClinicalTrials.gov registry entry for NCT04973605 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 153-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (61% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Sonrotoclax is the first listed.
NCT04973605 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT04973605 about?
NCT04973605 is a clinical study titled "A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma". The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14). The study investigates sonrotoclax alone and in combinatio...
What is the current status of trial NCT04973605?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 246 participants. The study started on 2021-09-16. Estimated completion is 2026-11.
What conditions does trial NCT04973605 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT04973605?
The interventions under investigation include: Sonrotoclax (DRUG), Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT04973605?
This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04973605 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.